热门资讯> 正文
Ionis Pharmaceuticals表示，Donidalorsen在遗传性血管性水肿患者中的3期OASISplus前瞻性转换研究的结果发表在《过敏与临床免疫学实践》杂志上
2025-07-21 19:05
- Results indicate that patients who switched to donidalorsen from prior prophylactic treatments showed a 62% further reduction in mean monthly HAE attack rate from baseline, and 84% of patients surveyed reported preference for donidalorsen.
- Patients switched to donidalorsen without increased breakthrough attacks and experienced further reductions in mean attack rate from baseline.
- Donidalorsen is currently under review with the U.S. FDA as a potential first-in-class prophylactic treatment for HAE; PDUFA date August 21
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
